Nasopharyngeal News and Research

RSS

Cell Medica enters EBV-associated cancer research collaboration with CAGT and Baylor College of Medicine

Cell Medica, a leading cellular therapeutics company which develops, manufactures and markets cellular immunotherapy products for the treatment of infectious disease and cancer, is pleased to announce an exclusive license agreement and research collaboration with the Center for Cell and Gene Therapy (CAGT), Baylor College of Medicine (Houston, Texas), for the commercialization of an innovative cell-based treatment for cancers associated with the oncogenic Epstein Barr virus (EBV).

7 Jan 2011

FDA grants 510(k) clearance to Focus Diagnostics Simplexa Flu A/B & RSV test on 3M Integrated Cycler

Quest Diagnostics Incorporated, the world's leading provider of diagnostic testing, information and services, today announced that the U.S. Food and Drug Administration (FDA) has issued 510(k) clearance to the Focus Diagnostics Simplexa Flu A/B & RSV test on the 3M™ Integrated Cycler. The Simplexa test, developed and manufactured by Quest Diagnostics' Focus Diagnostics business, is intended as an aid in the detection and discrimination of influenza A, influenza B and RSV virus infections.

From Quest Diagnostics 2 Dec 2010

Bacterial study confirms TLR2 signaling vital for activating human airway epithelial cells

Researchers from the Boston University School of Medicine (BUSM) have demonstrated that commensal species of the genus Neisseriae are low inducers of human airway epithelial cell responses as compared to the pathogenic species.

24 Nov 2010

Viral microRNA allows EBV to hide within cells and evade immune system

While most commonly associated with mononucleosis, Epstein-Barr virus (EBV) has been linked to many diseases that affect people long after the initial infection takes place, including some forms of cancer. In the current issue of the Journal of Biological Chemistry, scientists at The Wistar Institute describe how viral microRNA - small segments of RNA that suppress the effects of gene activity - allows EBV to hide within cells and evade the immune system.

26 Oct 2010

Chongqing Cancer Hospital commences treatment with Varian's RapidArc radiotherapy

Chongqing Cancer Hospital in Southwest China has become the first treatment center in Southwest China to offer cancer patients a faster, more precise form of image-guided radiotherapy that potentially enables doctors to improve outcomes while extending more advanced care to more patients. Clinicians at the hospital have used RapidArc® radiotherapy from Varian Medical Systems to treat patients for cancers of the nasopharynx, cervix, breast, and lung.

11 Oct 2010

Quidel receives FDA clearance for QuickVue RSV 10 immunoassay test

Quidel Corporation, a leading provider of rapid diagnostic testing solutions, announced today that it has received 510(k) clearance from the United States Food and Drug Administration (FDA) for the sale of its QuickVue RSV 10, a lateral flow immunoassay test for the qualitative detection of acute respiratory syncytial virus (RSV) infections.

29 Sep 2010

Researchers discover evolutionary nature of bacteria to spread chronic infectious disease

Researchers from the Center for Genomic Sciences at Allegheny General Hospital (AGH) in Pittsburgh have made a landmark discovery about the evolutionary nature of bacteria in the setting of chronic infectious disease. Reporting today in the journal PLos Pathogens, the AGH team documents for the first time that bacteria engage in a process called horizontal gene transfer to evolve rapidly during the course of a single infection.

18 Sep 2010

Fluctuation in PCV-7 vaccine dosing time increases pneumococcal serotype 19A strains: Study

Infants who received heptavalent pneumococcal conjugate vaccination (PCV-7) at 2, 4, and 11 months were more likely than unvaccinated controls to have nasopharyngeal (in the nasal passages and upper part of the throat behind the nose) acquisition of pneumococcal serotype 19A, a leading cause of respiratory pneumococcal disease, according to a study in the September 8 issue of JAMA.

8 Sep 2010

Genta presents tesetaxel dose-ranging trial results at ASCO 2010

Genta Incorporated announced today the presentation of results from two dose-ranging trials of tesetaxel, the Company's novel oral tubulin inhibitor. Results showed potential activity in patients with taxane-resistant cancers, along with no evidence of hypersensitivity and a low incidence of nerve damage, both of which are common side effects of standard taxanes.

8 Jun 2010

Scientists identify new susceptibility genes in genome-wide association study of nasopharyngeal carcinoma

Scientists from Singapore, China and USA have identified three new susceptibility genes in a genome-wide association study of nasopharyngeal carcinoma (NPC). The study, led by the Genome Institute of Singapore (GIS), a biomedical research institute of the Agency for Science, Technology and Research (A*STAR), and the Sun Yat-Sen University Cancer Centre, identified genetic risk factors of NPC that advance the understanding of the important role played by host genetic variation in influencing the susceptibility to this cancer.

31 May 2010

FDA issues 510(k) clearance to Simplexa Influenza A H1N1 (2009) test on 3M Integrated Cycler

Quest Diagnostics Incorporated, the world's leading provider of diagnostic testing, information and services, today announced that the U.S. Food and Drug Administration has issued 510(k) clearance to the Simplexa Influenza A H1N1 (2009) test on the 3M Integrated Cycler. The Simplexa test, developed and manufactured by Quest Diagnostics' Focus Diagnostics business, is the first to be cleared by the FDA for use as an aid in the detection and differentiation of influenza A and 2009 H1N1 influenza viral RNA.

25 May 2010

New study shows DFA testing for H1N1 influenza unreliable in ICU patients

Direct Immunofluorescence Assay testing for H1N1 influenza is unreliable in ICU patients, according to a new study from Stanford University. Multiple methods exist for diagnosing influenza, but data on the utility and accuracy of these tests for H1N1 are still emerging, given the relatively recent onset of the epidemic.

18 May 2010

Health Canada grants Response Biomedical Class 3 Medical Device license for RAMP RSV Assay

Response Biomedical Corporation today announced that it has been granted a Class 3 (near patient/point-of-care) Medical Device license by Health Canada to market its RAMP® Respiratory Syncytial Virus (RSV) Assay in Canada.

18 May 2010

FDA grants EUA for IQuum's Liat Influenza A/2009 H1N1 Assay

IQuum, Inc. today announced it has been granted an Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for its Liat™ Influenza A/2009 H1N1 Assay. The assay detects and differentiates 2009 H1N1 influenza viral RNA starting from collected nasopharyngeal swab samples in less than 30 minutes.

10 May 2010

InvestorSoup.com: CYCC's total revenues for third-quarter of 2009 decrease by 14%

InvestorSoup.com announces an investment report featuring Cyclacel Pharmaceuticals Inc. The report includes financial, comparative and investment analyses, and pertinent industry information you need to know to make an educated investment decision.

18 Mar 2010

Baxter International, DVC present Phase III clinical efficacy data for PREFLUCEL

Baxter International Inc., in conjunction with DynPort Vaccine Company LLC, a CSC Company, today presented Phase III study data measuring the clinical efficacy for PREFLUCEL, a trivalent seasonal influenza candidate vaccine. PREFLUCEL is made using Baxter’s Vero cell culture platform and does not contain an adjuvant or preservatives. The data were presented at the International Congress on Infectious Disease (ICID) in Miami, Florida.

From Baxter International Inc. 12 Mar 2010

FDA grants Diagnostic Hybrids emergency use authorization for 2009 H1N1 Influenza A Virus ID Kit

Diagnostic Hybrids, a Quidel Company has received emergency use authorization from the U.S. Food and Drug Administration for its D3® UltraTM 2009 H1N1 Influenza A Virus ID Kit, a monoclonal antibody fluorescent staining kit for the specific identification of 2009 H1N1 influenza A in direct patient specimens or incubated tissue cultures.

23 Feb 2010

Principio, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center sign technology licensing agreement

Principio Inc., a privately held emerging company developing novel molecular imaging agents and therapeutic radiopharmaceuticals for the treatment of cancer, today announced that the Company has obtained an exclusive license to several technologies developed at Johns Hopkins Sidney Kimmel Comprehensive Cancer Center.

11 Feb 2010

Idaho Technology commences clinical trials of FilmArray RP

Idaho Technology, Inc. (ITI) announced today that clinical trials of the FilmArray Respiratory Panel (RP) have commenced at three US Hospital Laboratories.

27 Jan 2010

Presence of Streptococcus pneumoniae could predict risk of severe disease in H1N1 pandemic influenza

The presence of the Streptococcus pneumoniae in samples that can be easily obtained in clinics and emergency rooms may predict risk of severe disease in H1N1 pandemic influenza.

31 Dec 2009